Mesoblast Wins FDA IND Clearance To Fast-Track Ryoncil Trial In Duchenne Muscular Dystrophy

AI Briefing

• – Mesoblast wins FDA IND clearance to fast-track Ryoncil trial in Duchenne muscular dystrophy.
• – The trial will assess the safety and efficacy of Ryoncil in patients with Duchenne muscular dystrophy.
• – The registrational clinical trial is expected to begin in the second half of 2023.